RXRX/ 12/17/2025 · 6:32 AM JPMorgan Turns Bullish on Recursion Pharmaceuticals JPMorgan upgrades Recursion Pharmaceuticals to Overweight, raises price target to $11, and highlights blockbuster potential for REC-4881 and promising early cancer data.